Study of IBI363 in Patients with Advanced First-line Gastric Cancer
This is a phase 1b study designed to evaluate the safety, tolerability and efficacy of IBI363 in combination with oxaliplatin and capecitabine (XELOX) in first-line treatment of unresectable advanced or metastatic gastric and gastroesophageal junction adenocarcinoma.
IBI363 + Chemotherapy
DRUG: IBI363
Objective response rate (ORR), The efficacy of solid tumors was evaluated according to RECIST v1.1, Through out the study (up to 2 years)|Disease control rate (DCR), The efficacy of solid tumors was evaluated according to RECIST v1.1, Through out the study (up to 2 years)
Progression Free Survival（PFS）;, The efficacy of solid tumors was evaluated according to RECIST v1.1, Up to 2 years|Overall Survival, OS）, The efficacy of solid tumors was evaluated according to RECIST v1.1, Up to 2 years|Adverse Enent (AE), Treatment-Emergent AE (TEAE), Adverse Event of Special Interest (AESI) and Serious Adverse Event (SAE), Adverse events will be assessed by investigator(s) according to NCI-CTCAE v5.0., Up to 90 days after the last administration
This is a phase 1b study designed to evaluate the safety, tolerability and efficacy of IBI363 in combination with oxaliplatin and capecitabine (XELOX) in first-line treatment of unresectable advanced or metastatic gastric and gastroesophageal junction adenocarcinoma.